儿童急性T淋巴细胞白血病（T-ALL）的无事件生存率（EFS）显著低于急性B淋巴细胞白血病（B-ALL），且 T-ALL诱导失败、早期死亡、复发等风险显著高于B-ALL。近年来，各协作组不断调整治疗方案，如使用地塞米松代替泼 尼松、应用大剂量甲氨喋呤、监测MRD水平、应用靶向药物等，极大地改善了T-ALL患儿的临床预后。文章综述国内外协 作组治疗儿童T-ALL最新临床方案及研究结果。

　The event-free survival rate (EFS) of childhood acute T-lymphocytic leukemia (T-ALL) was significantly lower than that of acute B-lymphocytic leukemia (B-ALL), and the risk of induction failure, early death, and recurrence of childhood T-ALL was significantly higher than that of B-ALL. In recent years, various collaborative groups have continuously adjusted treatment options including using dexamethasone instead of prednisone, applying high-dose methotrexate, monitoring MRD levels, and applying targeted drugs, which have greatly improved the clinical prognosis of childhood T-ALL. This article summarizes the proposals and results of different collaborative groups' treatments of childhood T-ALL.